Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 24;22(1):122.
doi: 10.3390/ijms22010122.

Tracking the Genetic Susceptibility Background of B-Cell Non-Hodgkin's Lymphomas from Genome-Wide Association Studies

Isaias Hernández-Verdin  1   2 , Karim Labreche  1   2 , Marion Benazra  1   2   3   4   5 , Karima Mokhtari  6   7 , Khê Hoang-Xuan  1   2   3   4   7   8 , Agusti Alentorn  1   2   3   4   7
Affiliations
Review

Tracking the Genetic Susceptibility Background of B-Cell Non-Hodgkin's Lymphomas from Genome-Wide Association Studies

Isaias Hernández-Verdin et al. Int J Mol Sci. .

Abstract

B-cell non-Hodgkin's lymphoma (NHL) risk associations had been mainly attributed to family history of the disease, inflammation, and immune components including human leukocyte antigen (HLA) genetic variations. Nevertheless, a broad range of genome-wide association studies (GWAS) have shed light into the identification of several genetic variants presumptively associated with B-cell NHL etiologies, survival or shared genetic risk with other diseases. The present review aims to overview HLA structure and diversity and summarize the evidence of genetic variations, by GWAS, on five NHL subtypes (diffuse large B-cell lymphoma DLBCL, follicular lymphoma FL, chronic lymphocytic leukemia CLL, marginal zone lymphoma MZL, and primary central nervous system lymphoma PCNSL). Evidence indicates that the HLA zygosity status in B-cell NHL might promote immune escape and that genome-wide significance variants can give biological insight but also potential therapeutic markers such as WEE1 in DLBCL. However, additional studies are needed, especially for non-DLBCL, to replicate the associations found to date.

Keywords: B-cell non-Hodgkin’s lymphoma; GWAS; HLA; cancer risk.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic map of the human leukocyte antigen (HLA) genomic region showing the distribution of HLA genes along with the summarized mechanism of antigen presentation.
See this image and copyright information in PMC

Similar articles

  • Lipid Trait Variants and the Risk of Non-Hodgkin Lymphoma Subtypes: A Mendelian Randomization Study.
    Kleinstern G, Camp NJ, Berndt SI, Birmann BM, Nieters A, Bracci PM, McKay JD, Ghesquières H, Lan Q, Hjalgrim H, Benavente Y, Monnereau A, Wang SS, Zhang Y, Purdue MP, Zeleniuch-Jacquotte A, Giles GG, Vermeulen R, Cocco P, Albanes D, Teras LR, Brooks-Wilson AR, Vajdic CM, Kane E, Caporaso NE, Smedby KE, Salles G, Vijai J, Chanock SJ, Skibola CF, Rothman N, Slager SL, Cerhan JR. Kleinstern G, et al. Cancer Epidemiol Biomarkers Prev. 2020 May;29(5):1074-1078. doi: 10.1158/1055-9965.EPI-19-0803. Epub 2020 Feb 27. Cancer Epidemiol Biomarkers Prev. 2020. PMID: 32108027 Free PMC article.
  • HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes.
    Wang SS, Carrington M, Berndt SI, Slager SL, Bracci PM, Voutsinas J, Cerhan JR, Smedby KE, Hjalgrim H, Vijai J, Morton LM, Vermeulen R, Paltiel O, Vajdic CM, Linet MS, Nieters A, de Sanjose S, Cozen W, Brown EE, Turner J, Spinelli JJ, Zheng T, Birmann BM, Flowers CR, Becker N, Holly EA, Kane E, Weisenburger D, Maynadie M, Cocco P, Albanes D, Weinstein SJ, Teras LR, Diver WR, Lax SJ, Travis RC, Kaaks R, Riboli E, Benavente Y, Brennan P, McKay J, Delfau-Larue MH, Link BK, Magnani C, Ennas MG, Latte G, Feldman AL, Doo NW, Giles GG, Southey MC, Milne RL, Offit K, Musinsky J, Arslan AA, Purdue MP, Adami HO, Melbye M, Glimelius B, Conde L, Camp NJ, Glenn M, Curtin K, Clavel J, Monnereau A, Cox DG, Ghesquières H, Salles G, Bofetta P, Foretova L, Staines A, Davis S, Severson RK, Lan Q, Brooks-Wilson A, Smith MT, Roman E, Kricker A, Zhang Y, Kraft P, Chanock SJ, Rothman N, Hartge P, Skibola CF. Wang SS, et al. Cancer Res. 2018 Jul 15;78(14):4086-4096. doi: 10.1158/0008-5472.CAN-17-2900. Epub 2018 May 7. Cancer Res. 2018. PMID: 29735552 Free PMC article.
  • GWAS of follicular lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma.
    Smedby KE, Foo JN, Skibola CF, Darabi H, Conde L, Hjalgrim H, Kumar V, Chang ET, Rothman N, Cerhan JR, Brooks-Wilson AR, Rehnberg E, Irwan ID, Ryder LP, Brown PN, Bracci PM, Agana L, Riby J, Cozen W, Davis S, Hartge P, Morton LM, Severson RK, Wang SS, Slager SL, Fredericksen ZS, Novak AJ, Kay NE, Habermann TM, Armstrong B, Kricker A, Milliken S, Purdue MP, Vajdic CM, Boyle P, Lan Q, Zahm SH, Zhang Y, Zheng T, Leach S, Spinelli JJ, Smith MT, Chanock SJ, Padyukov L, Alfredsson L, Klareskog L, Glimelius B, Melbye M, Liu ET, Adami HO, Humphreys K, Liu J. Smedby KE, et al. PLoS Genet. 2011 Apr;7(4):e1001378. doi: 10.1371/journal.pgen.1001378. Epub 2011 Apr 21. PLoS Genet. 2011. PMID: 21533074 Free PMC article.
  • High-grade transformation of low-grade non-Hodgkin's lymphomas: mechanisms of tumor progression.
    Matolcsy A. Matolcsy A. Leuk Lymphoma. 1999 Jul;34(3-4):251-9. doi: 10.3109/10428199909050950. Leuk Lymphoma. 1999. PMID: 10439362 Review.
  • Molecular pathways in low grade B-cell lymphoma.
    Gaidano G, Pastore C, Capello D, Cilli V, Saglio G. Gaidano G, et al. Leuk Lymphoma. 1997 Dec;26 Suppl 1:107-13. doi: 10.3109/10428199709058607. Leuk Lymphoma. 1997. PMID: 9570687 Review.
See all similar articles

Cited by

References

    1. Al-Naeeb A.B., Ajithkumar T., Behan S., Hodson D. Non-Hodgkin lymphoma. BMJ. 2018;362:k3204. doi: 10.1136/bmj.k3204. - DOI - PubMed
    1. Hoang-Xuan K., Bessell E., Bromberg J.E.C., Hottinger A.F., Preusser M., Rudà R., Schlegel U., Siegal T., Soussain C., Abacioglu U., et al. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: Guidelines from the European Association for Neuro-Oncology. Lancet Oncol. 2015;16:e322–e332. doi: 10.1016/S1470-2045(15)00076-5. - DOI - PubMed
    1. Smedby K.E. Epidemiology and etiology of non-Hodgkin lymphoma—A review. Acta Oncol. 2006;45:258–271. doi: 10.1080/02841860500531682. - DOI - PubMed
    1. Parihar A.S., Singh R., Shaik S., Negi B.S., Rajguru J.P., Patil P.B., Sharma U. Non-Hodgkin’s lymphoma: A review. J. Fam. Med. Prim. Care. 2020;9:1834–1840. doi: 10.4103/jfmpc.jfmpc_1037_19. - DOI - PMC - PubMed
    1. Swerdlow S.H., Campo E., Pileri S.A., Harris N.L., Stein H., Siebert R., Advani R., Ghielmini M., Salles G.A., Zelenetz A.D., et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390. doi: 10.1182/blood-2016-01-643569. - DOI - PMC - PubMed

MeSH terms